down arrow

Cellectar Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US15117F8077
USD
3.80
0.18 (4.97%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.613.83

52 Week

2.7144.70
Valuation
Technical
Day's Volume

CASH

14.12 k

Shareholding (Mar 2025)

FII

10.74%

Held by 11 FIIs

DII

84.36%

Held by 7 DIIs

Promoter

0.05%

How big is Cellectar Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Cellectar Biosciences, Inc. has a market capitalization of 16.19 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -24.54 million over the latest four quarters. The company reported shareholder's funds of 15.68 million and total assets of 25.47 million as of Dec 24.

Market Cap: As of Jun 18, Cellectar Biosciences, Inc. has a market capitalization of 16.19 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cellectar Biosciences, Inc. reported net sales of 0.00 million and a net profit of -24.54 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 15.68 million and total assets of 25.47 million.

Read More

What does Cellectar Biosciences, Inc. do?

22-Jun-2025

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments, with a market cap of $16.19 million and a recent net profit loss of $7 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.

Overview:<BR>Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 16.19 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.43 <BR>Return on Equity: -549.62% <BR>Price to Book: 1.68<BR><BR>Contact Details:<BR>Address: 100 Campus Dr, FLORHAM PARK NJ: 07932-1020 <BR>Tel: 1 608 4418120 <BR>Fax: 1 608 4418121 <BR>Website: http://cellectar.com

Read More

Who are in the management team of Cellectar Biosciences, Inc.?

22-Jun-2025

As of March 2022, Cellectar Biosciences, Inc.'s management team includes Mr. Douglas Swirsky (Independent Chairman), Mr. James Caruso (President and CEO), and five Independent Directors: Mr. Frederick Driscoll, Dr. Stephen Hill, Mr. Stefan Loren, and Mr. John Neis. This team combines key executives with independent oversight for structured leadership.

As of March 2022, the management team of Cellectar Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Douglas Swirsky, who serves as the Independent Chairman of the Board.<BR>- Mr. James Caruso, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Frederick Driscoll, who is an Independent Director.<BR>- Dr. Stephen Hill, who is also an Independent Director.<BR>- Mr. Stefan Loren, serving as an Independent Director.<BR>- Mr. John Neis, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and key executives, highlighting a structured leadership approach.

Read More

Is Cellectar Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cellectar Biosciences, Inc. shows a bullish trend supported by positive RSI readings, though it has significantly underperformed the S&P 500 with a 1-year return of -91.29% and a 5-year return of -98.49%.

As of 8 September 2025, the technical trend for Cellectar Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this view being the weekly and monthly RSI readings, both of which are bullish. However, the MACD remains mildly bullish on both weekly and monthly time frames, indicating some caution. The Dow Theory shows a mixed picture with a mildly bullish weekly signal but a bearish monthly signal. <BR><BR>Despite the bullish trend, the stock has underperformed significantly compared to the S&P 500 over various periods, with a 1-year return of -91.29% versus the S&P 500's 17.14%, and a staggering 5-year return of -98.49% compared to the S&P 500's 96.61%. This suggests that while the current technical indicators are bullish, the overall performance remains weak relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 16 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.47

stock-summary
Return on Equity

-609.79%

stock-summary
Price to Book

2.15

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.5%
0%
-20.5%
6 Months
-54.37%
0%
-54.37%
1 Year
-91.32%
0%
-91.32%
2 Years
-95.07%
0%
-95.07%
3 Years
-93.23%
0%
-93.23%
4 Years
-97.93%
0%
-97.93%
5 Years
-99.46%
0%
-99.46%

Cellectar Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cellectar Biosciences, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Cellectar Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this view being the weekly and monthly RSI readings, both of which are bullish. However, the MACD remains mildly bullish on both weekly and monthly time frames, indicating some caution. The Dow Theory shows a mixed picture with a mildly bullish weekly signal but a bearish monthly signal. Despite the bullish trend, the stock has underperformed significantly compared to the S&P 500 over various periods, with a 1-year return of -91.29% versus the S&P 500's 17.14%, and a staggering 5-year return of -98.49% compared to the S&P 500's 96.61%. This suggests that while the current technical indicators are bullish, the overall performance remains weak relative to the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-189.66%
EBIT to Interest (avg)
-28.39
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.43
Sales to Capital Employed (avg)
0
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
36.77%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.73
EV to EBIT
-0.06
EV to EBITDA
-0.06
EV to Capital Employed
-0.67
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-549.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (4.84%)

Foreign Institutions

Held by 11 Foreign Institutions (10.74%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -500.00% vs 89.02% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.00",
          "val2": "-13.60",
          "chgp": "55.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.50",
          "val2": "12.50",
          "chgp": "-96.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.40",
          "val2": "-0.90",
          "chgp": "-500.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.21% vs -34.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-51.50",
          "val2": "-38.80",
          "chgp": "-32.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "13.80",
          "val2": "-3.80",
          "chgp": "463.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.60",
          "val2": "-42.80",
          "chgp": "-4.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.00
-13.60
55.88%
Interest
0.00
0.00
Exceptional Items
0.50
12.50
-96.00%
Consolidate Net Profit
-5.40
-0.90
-500.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -500.00% vs 89.02% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-51.50
-38.80
-32.73%
Interest
0.00
0.00
Exceptional Items
13.80
-3.80
463.16%
Consolidate Net Profit
-44.60
-42.80
-4.21%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4.21% vs -34.59% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cellectar Biosciences, Inc. stock-summary
stock-summary
Cellectar Biosciences, Inc.
Pharmaceuticals & Biotechnology
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.
Company Coordinates stock-summary
Company Details
100 Campus Dr , FLORHAM PARK NJ : 07932-1020
stock-summary
Tel: 1 608 4418120
stock-summary
http://cellectar.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."